In a suburban Chicago clinic, patients seeking fertility treatment are being offered something beyond the standard IVF playbook: peptide protocols, AI-driven diagnostics, and a pitch that frames reproduction not just as family-building, but as a window into whole-body health.
That's the premise behind Onto Health, a startup that just closed a $20 million Series A round, co-led by ARTIS Ventures and Humania. The deal, which closed on April 15, positions the company to expand across the United States while planting a flag in the Gulf Cooperation Council region—a geography where fertility care meets strict cultural norms and surging medical investment.
The funding announcement, light on details like valuation or the full investor list, signals expansion ambitions that extend beyond a typical fertility clinic rollup. Onto Health is positioning itself at the intersection of reproductive medicine and longevity science, a framing that's either prescient or a bit ahead of its time. Maybe both.
The Money and the Partners
ARTIS Ventures didn't just invest in Onto Health—it co-founded the company alongside CEO Dr. Roohi Jeelani, a double board-certified reproductive endocrinologist with a personal history of PCOS. The TechBio-focused firm's return as a Series A co-lead isn't surprising; venture firms that help build companies rarely bow out early.
Humania, the round's other anchor, brings something different to the table: a sprawling healthcare infrastructure across the Middle East and North Africa. The investment platform, tied to Saudi German Health, operates eighteen tertiary hospitals and more than 50 outpatient facilities in the GCC. Aamir Rehan, Humania's CEO, framed the investment through the lens of regional expansion. Makarem S. Batterjee, founder and president of Humania—and vice chairman of the Saudi German Group—emphasized bringing the technology to Gulf markets, where fertility treatment carries particular cultural and regulatory complexity.
Stuart Peterson, ARTIS's founder and managing partner, highlighted clinical rigor and compassion in the announcement, the kind of language that sounds like mission statement but also reflects real investor concerns in a field where outcomes matter deeply to patients.
What They're Actually Building
Formally established in its current form in January 2026 with Dr. Jeelani as founder and CEO, and based in Parker, Colorado, Onto Health runs clinics in Illinois and Colorado. The Chicago operation centers on a location at 371 W Ontario Street, with planned monitoring sites spreading into Park Ridge, Hoffman Estates, and Naperville. Colorado operations continue in Englewood and Fort Collins, though the company's growth ambitions clearly tilt toward the Midwest.
The service menu reads like most fertility clinics: egg freezing, IUI, IVF, preimplantation genetic testing, male infertility treatment, donor support. But the company layers in AI-driven diagnostics and what it calls clinical automation—tools meant to personalize treatment plans and, in theory, improve outcomes.
Then there's the longevity angle. Onto Health references "targeted peptide protocols among emerging therapies," a phrase that nods toward regenerative medicine without getting too specific. It's the kind of integrative health language that either signals innovation or raises eyebrows, depending on who's listening.
Beyond patient care, the company runs Onto Learning, a clinician education platform, and sells supplements—revenue streams that diversify the business model but also raise questions about where clinical care ends and wellness commerce begins.
Dr. Jeelani, formally named founder and CEO in January when the Chicago expansion was announced, brings credibility that matters in a field where trust is everything. Her company profile notes her focus on a proactive, whole-health approach to fertility, a philosophy that seems to permeate the startup's broader positioning.
The Expansion Playbook
The $20 million will chase two priorities: deeper U.S. market penetration and a Gulf region launch. Job postings from mid-March showed openings for fertility nurses in Hoffman Estates and Park Ridge, the kind of ground-level hiring that signals operational scale-up. LinkedIn data from April pegged the company at 11-50 employees, a small team for a venture-backed fertility provider with multi-region ambitions.
The GCC expansion leans heavily on Humania's expertise and infrastructure. It's a geography where fertility treatment intersects with cultural sensitivities, government healthcare investment, and a growing appetite for medical tourism. Whether Onto Health's longevity-infused model translates across that landscape remains an open question.
The timing aligns with broader trends. U.S. digital health funding hit $14.2 billion in 2025, up 35% year-over-year, with AI-focused companies claiming outsized share. Fertility care, already a venture darling, is increasingly bundled with AI diagnostics and precision medicine narratives. Onto Health is riding that wave, though perhaps with a sharper integrative health edge than most.
A Crowded, Well-Funded Field
The fertility market isn't exactly underserved by venture capital. ARTIS itself led Conceivable Life Sciences' $18 million Series A in January 2025, backing an AI-powered automated IVF lab. Posterity Health raised $13 million the following month for male reproductive care. The deals keep coming, each with its own technological twist or care model differentiation.
What sets Onto Health apart—if it does—is the explicit weaving of fertility and longevity. Most fertility startups focus narrowly on reproductive outcomes: embryo quality, pregnancy rates, live birth statistics. Onto Health frames fertility as a marker of overall health, a signal that something larger might be amiss or optimized. It's a compelling idea, one that could resonate with patients who see fertility struggles as part of a broader wellness puzzle.
Whether that resonates with payers is another matter entirely. Insurance coverage for fertility treatment remains patchy, and adding longevity protocols to the mix doesn't simplify reimbursement conversations. The company's supplements and education platforms suggest it's building revenue lines that don't depend entirely on insurance—a hedge, perhaps, against the realities of U.S. healthcare economics.
As Onto Health scales into new markets, two things will become clearer: whether patients buy into the longevity positioning, and whether the company can deliver clinical outcomes that justify the more expansive framing. For now, it has $20 million and two well-connected investors betting that fertility care is ready for a philosophical expansion.
